株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

全ゲノム&エクソームシーケンシングの世界市場:研究・臨床・DTC・アグリバイオ・腫瘍細胞用途

Whole Genome and Exome Sequencing Markets by Research, Clinical, Direct to Consumer, AgriBio & Tumor with Executive and Consultant Guides 2020 to 2024

発行 Howe Sound Research 商品コード 567248
出版日 ページ情報 英文 485 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
全ゲノム&エクソームシーケンシングの世界市場:研究・臨床・DTC・アグリバイオ・腫瘍細胞用途 Whole Genome and Exome Sequencing Markets by Research, Clinical, Direct to Consumer, AgriBio & Tumor with Executive and Consultant Guides 2020 to 2024
出版日: 2019年11月02日 ページ情報: 英文 485 Pages
概要

当レポートでは、世界の全ゲノムおよびエクソームシーケンシングの市場を調査し、市場および技術の概要、各種関連事業者・組織・機関とその役割、各種用途と導入事例、産業構造、主要企業、市場成長への各種影響因子の分析、企業および研究機関などの近年の取り組み、地域/主要国別の実施件数・価格・収益規模の推移と予測、将来の展望などをまとめています。

第1章 イントロダクション・市場の定義

第2章 市場概要

  • 関連事業者と役割
  • 用途・例・ディスカッション
    • DTC
    • 研究
    • 臨床
    • 病原体検査
    • アグリバイオ
  • 産業構造
  • 主要企業のプロファイル

第3章 市場動向

  • 市場成長促進因子
  • 市場成長抑制因子
  • シーケンシング装置

第4章 WGES (全ゲノム&エクソームシーケンシング):近年の展開

第5章 北米市場の分析・予測

  • 件数・価格・収益:用途・国別
    • 米国
    • カナダ
      • 研究
      • 臨床
      • アグリバイオ
      • DTC検査
      • 腫瘍細胞

第6章 欧州市場の分析・予測

  • 件数・価格・収益:用途・国別
    • フランス
    • ドイツ
    • 英国
    • スペイン
    • イタリア
    • ロシア
    • その他の欧州・旧ソ連
      • 研究
      • 臨床
      • アグリバイオ
      • DTC検査
      • 腫瘍細胞

第7章 アジア太平洋市場の分析・予測

  • 件数・価格・収益:用途・国別
    • 中国
    • 日本
    • 韓国
    • インド
    • オーストラリア
    • その他
      • 研究
      • 臨床
      • アグリバイオ
      • DTC検査
      • 腫瘍細胞

第8章 ラテンアメリカ・アフリカ・中東市場の分析・予測

  • 件数・価格・収益:用途・地域別
    • 研究
    • 臨床
    • アグリバイオ
    • DTC検査
    • 腫瘍細胞

第9章 世界市場の分析・予測:サマリー

  • 件数・価格・収益:用途別
    • 研究
    • 臨床
    • アグリバイオ
    • DTC検査
    • 腫瘍細胞

第10章 全ゲノムシーケンシング:将来のビジョン

付録

図表

Table of Tables

  • Table 1 The Base Pairs
  • Table 2 Most Common Traditional Genetic Disorders
  • TABLE 3 LAB SPENDING 2014 TO 2024
  • Table 4 List of GLOBAL SEQUENCING LOCATIONS
  • Table 5 Market Players by Type
  • Table 6 The Different Markets for Whole Genome Sequencing
  • Table 7 DTC Sub Segments
  • Table 8 Roles of WGS in AgriBio
  • Table 9 The Factors Driving Growth
  • Table 10 Factors Limiting Growth
  • Table 11 - Listing of Current NGS Instrument Specifications
  • Table 12 Six New Sequencing Technologies
  • Table 13 Market by Country
  • TABLE 14 GLOBAL MARKET BY APPLICATION
  • TABLE 15 RESEARCH SEGMENT BY COUNTRY
  • TABLE 16 CLINICAL SEGMENT BY COUNTRY
  • TABLE 17 TUMOR SEGMENT BY COUNTRY
  • TABLE 18 DT WGES SEGMENT BY COUNTRY
  • TABLE 19 AGRI/OTHER SEGMENT BY COUNTRY
  • TABLE 20 GENOME SEGMENT BY COUNTRY
  • TABLE 21 EXOME SEGMENT BY COUNTRY
  • TABLE 22 OTHER COVERAGE SEGMENT BY COUNTRY
  • Table 23 2019 Clinical Lab Fee Schedule

Table of Figures

  • FIGURE 1 CLINICAL LAB SPENDING 2014 TO 2024
  • Figure 2 Size of Genome for Various Species
  • Figure 3 - Cost To Sequence a Human Genome
  • FIGURE 4 APPLICATION SHARE BY YEAR
  • FIGURE 5 APPLICATION SEGMENT GROWTH RATES
  • FIGURE 6 SEGMENT SHARE SHIFTS
  • FIGURE 7 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 8 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 9 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 10 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 11 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 12 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 13 SEGMENT VS. TOTAL MARKET GROWTH
  • FIGURE 14 SEGMENT VS. TOTAL MARKET GROWTH
目次

OVERVIEW:

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices?

Our facts and support = Your success.

A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Whole Genome Sequencing Market - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 Whole Genome Sequencing Definition In This Report
    • 1.1.1 Whole and Exome Sequencing
    • 1.1.2 Research and Clinical
    • 1.1.3 Direct to Consumer
    • 1.1.4 AgriBio
    • 1.1.5 Tumor Cells
  • 1.2 The Genomics Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1 U.S. Medicare Expenditures for laboratory testing
  • 1.5 Sizing the Genome - Not What You Think
    • 1.5.1 Cost, Price and Genome Size, Pricing Practice
      • 1A GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE - Location & Contacts

2. Market Overview

  • 2.1 Market Participants Play Different Roles
    • 2.1.1 Instrument Manufacturer
    • 2.1.2 Independent lab specialized/esoteric
    • 2.1.3 Independent lab national/regional
    • 2.1.4 Independent lab analytical
    • 2.1.5 Public National/regional lab
    • 2.1.6 Hospital lab
    • 2.1.7 Physician lab
    • 2.1.8 DTC Lab
    • 2.1.9 Sequencing Labs
    • 2.1.10 Audit body
  • 2.2 Whole Genome Sequencing -Markets, Examples and Discussion
    • 2.2.1 Direct to Consumer - Two Approaches
      • 2.2.1.1 The New Age of Medical Information
      • 2.2.1.2 Dangers in DTC-WGS - Health Costs and Regulation
      • 2.2.1.3 Newborn and Prenatal - A Brave New World
      • 2.2.1.4 DTC - How Many Segments?
    • 2.2.2 Research Markets
      • 2.2.2.1 Research Funding and Capital Expense
      • 2.2.2.2 WGS Datasets Preferred
      • 2.2.2.3 Existing research repurposed
      • 2.2.2.4 Organism Wide Market
      • 2.2.2.5 Service Suppliers Respond
    • 2.2.3 Clinical - Understanding Germline and Somatic
      • 2.2.3.1 Somatic - Chasing Mutations and Pharmacogenomics
    • 2.2.4 Pathogen Testing
      • 2.2.4.1 The Hepatitis C Story
      • 2.2.4.2 Will the Microbiology Department Disappear?
    • 2.2.5 AgriBio - Big Business
      • 2.2.5.1 GMO is Here to Stay
      • 2.2.5.2 WGS Benefits and Risks
      • 2.2.5.3 The New Agriculture
  • 2.3 Industry Structure
    • 2.3.1 Hospital's Testing Share
    • 2.3.2 Economies of Scale
    • 2.3.3 Instrument Manufacturer Role
    • 2.3.4 Healthcare Industry Impacts - Still Struggling
      • 2.3.4.1 Can the Healthcare Industry Adapt?
      • 2.3.4.2 Genetic Counselling as an Industry
      • 2.3.4.3 WGES Adoption and Cannibalization
      • 2.3.4.4 The Meaning of Grail

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Diagnostic Factors
    • 3.1.2 Interpreting the Code Otherwise.
    • 3.1.3 Changes in Agriculture.
    • 3.1.4 Fertility Technology Comes of Age
    • 3.1.5 Pathogen Challenges
  • 3.2 Factors Limiting Growth
    • 3.2.1 Increased Competition Lowers Price
    • 3.2.2 Lower Costs
    • 3.2.3 Healthcare Cost Concerns Curtail Growth.
    • 3.2.4 Wellness has a downside
    • 3.2.5 GMO Opposition Movement.
  • 3.3 Sequencing Instrumentation
    • 3.3.1 Instrumentation Tenacity.
    • 3.3.2 Declining Cost of Instruments Changes Industry Structure.
    • 3.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS.
    • 3.3.4 Oxford Nanopore
      • 3.3.4.1 What is Oxford Nanopore Sequencing?
      • 3.3.4.2 What can Oxford Nanopore Sequencingt be used for?
      • 3.3.4.3 Oxford Nanopore Products
    • 3.3.5 Long Reads - Further Segmentation
    • 3.3.6 Linked Reads
    • 3.3.7 Targeted Sequencing Adopts CRISPR
    • 3.3.8 New Sequencing Technologies

4. WGES Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • UK Whole-Genome Sequencing Project Obtains £200M
      • WGS may help with disease outbreaks
      • Veritas Cuts WGS Price by 40%
      • Dante Labs Launches GenomeL, Long Reads Human Whole Genome Sequencing
      • Machine-learning system used to diagnose genetic diseases
      • Whole Genome Sequencing for healthy creates controversy
      • 100,000 whole genomes sequenced in the NHS
      • Nebula Genomics Offers FREE Whole Genome Sequencing
      • Veritas Genetics has time limited WGS offer for $199
      • Veritas Genetics Launches Two New Whole Genome Sequencing Products
      • BGI unveils a powerful new sequencer
      • State of California Funds $2M Whole-Genome Sequencing Pilot
      • Rapid genome sequencing could revolutionize health care
      • Human Longevity Launches Whole Genome Product, MassMutual Partnerships $1500 to sequence newborns in China
      • Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion
      • PerkinElmer Launches Clinical Whole Genome Sequencing Services
      • Nine Centres use Oxford Nanopore MinION to Sequence Human Genome
      • Esperite and BGI Genomics sign a strategic agreement to offer Whole Genome Sequencing on a large scale
      • Easily Affordable Whole-genome Sequencing is Goal of Mayo Collaboration with Veritas
      • Regeneron Partners With AbbVie, Alnylam, AstraZeneca, Biogen, Pfizer to Sequence UK Biobank Samples
      • MedGenome Expands Its NGS Capabilities and Forays Into Single-Cell Sequencing
      • Genomics England Adopts Edico's Dragen For NGS Analysis
      • BGI Says It Will Slash Cost of Gene Testing to $300
      • Position Statement Spells Out Fetal Diagnostic Sequencing Recommendations
      • Dante Labs Announces 10,000 European Genome Project

5. Profiles of Key Companies

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc. - A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd.
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

6. Global Market Size

  • 6.1 Global Market by Country
  • 6.2 Global Market by Application

7. Market Sizes by Application

  • 7.1 Research Market
  • 7.2 Clinical Market
  • 7.3 Tumor Market
  • 7.4 DTC WEGS Market
  • 7.5 Agribio & Other Market

8. Market Sizes by Coverage

  • 8.1 Genome Market
  • 8.2 Exome Market
  • 8.3 Other Coverage Market

9. Vision of the Future of Whole Genome Sequencing

Appendices

  • I. United States Medicare System: January 2019 laboratory Fees Schedule
  • II Methodology
  • II.1 Authors
  • II.2 Sources
Back to Top